EP. 2 MIRASOL Trial: Final OS Data for Mirvetuximab Soravtansine in FRa+ Platinum-Resistant Ovarian Cancer
November 15th, 2026Five Under 5: Top Oncology Videos for the Week of 11/8The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.Read more
November 11th, 2026First-Line Niraparib Maintenance Yields Longer PFS in HRD-Positive vs HRD-Negative Optimally Debulked Ovarian CancerRetrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.Read more
November 10th, 2026Mo-Rez Responses Span B7-H4 Expression Levels in Platinum-Resistant Ovarian Cancer in BEHOLD-1 Biomarker AnalysisExploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.Read more
November 10th, 2026Longer Follow-Up of BEHOLD-1 Shows Durable Responses With Mo-Rez in Platinum-Resistant Ovarian CancerUpdated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.Read more
November 9th, 2026UV1 Vaccine Data Keep hTERT in Focus as an Immunotherapy Target in Recurrent Ovarian CancerTrine Jakobi Nøttrup, MD, PhD, discusses data for the hTERT-directed vaccine UV1 in BRCA wild-type recurrent ovarian cancer/Read more